Pereira Lucas Borges, Gonçalves Ana Maria Rosa Freato, Fernandes Camila Stéfani Estancial, Fontanella Andréia Turmina, Francisco Priscila Maria Stolses Bergamo, Mengue Sotero Serrate, Borges Rogério Boff, Pizzol Tatiane da Silva Dal, Costa Karen Sarmento
Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
Departamento de Saúde Coletiva, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Einstein (Sao Paulo). 2020;18:eAO5314. doi: 10.31744/einstein_journal/2020ao5314. Epub 2020 Aug 10.
Objective To estimate the prevalence of use of drugs to treat gastrointestinal disorders, according to demographic, socioeconomic, and health characteristics of the Brazilian population. Methods This is a population-based survey that interviewed individuals residing in cities of the five regions in Brazil. The study sample was composed of 32,348 individuals aged 20 or more years. The profile of use of drugs for gastrointestinal disorders was evaluated considering the variables sex, age, healthcare plan, region, and number of chronic diseases. We also analyzed the frequency of individuals who declared using other drugs, besides those already employed for treatment of gastrointestinal disorders. Additionally, the estimated frequencies of the drug classes used were determined. Results The prevalence of use of drugs for gastrointestinal disorders in Brazil was 6.9% (95% confidence interval - 6.4-7.6), higher in females, among persons aged over 60 years, in those who had a private healthcare insurance, and presented with two or more chronic diseases. It was noted that 42.9% of the aged who used drugs for gastrointestinal disorders were also on polypharmacy. As to the classes of drugs, 82% corresponded to drugs for the food tract and metabolism, particularly proton pumps inhibitors. Conclusion The use of drugs for treatment of gastrointestinal disorders was significant among women and elderly. In this age group, consumption may be linked to gastric protection due to polypharmacy. This study is an unprecedented opportunity to observe the self-reported consumption profile of these drugs in Brazil and, therefore, could subsidize strategies to promote their rational use.
目的 根据巴西人口的人口统计学、社会经济和健康特征，估计治疗胃肠道疾病药物的使用 prevalence。方法 这是一项基于人群的调查，对居住在巴西五个地区城市的个人进行了访谈。研究样本由32348名20岁及以上的个体组成。考虑性别、年龄、医疗保健计划、地区和慢性病数量等变量，评估了胃肠道疾病药物的使用情况。我们还分析了除已用于治疗胃肠道疾病的药物外，宣称使用其他药物的个体的频率。此外，还确定了所用药物类别的估计频率。结果 巴西胃肠道疾病药物的使用 prevalence 为6.9%（95%置信区间 - 6.4 - 7.6），在女性、60岁以上人群、拥有私人医疗保险的人群以及患有两种或更多种慢性病的人群中更高。值得注意的是，使用胃肠道疾病药物的老年人中有42.9%也在使用多种药物。至于药物类别，82%对应于用于消化道和代谢的药物，特别是质子泵抑制剂。结论 治疗胃肠道疾病的药物在女性和老年人中使用显著。在这个年龄组中，消费可能与多种药物联合使用导致的胃保护有关。这项研究是观察巴西这些药物自我报告消费情况的前所未有的机会，因此可以为促进其合理使用的策略提供支持。
